Skip to main
  1. Stocks
  2. Retension Pharmaceuticals Inc
  3. Forecast
RTSN

RTSN Stock Forecast & Price Target

RTSN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Retension Pharmaceuticals is viewed favorably because RTN-001 has already shown clinically meaningful placebo-adjusted systolic blood pressure reductions of up to 12.8 mmHg across nine prior studies in over 265 subjects, with no drug-related serious adverse events and generally mild, transient tolerability findings. Its once-daily, oral, modified-release PDE5 mechanism is differentiated by improved penetration into central vasculature, potentially addressing an estimated 40 million underserved uncontrolled and treatment-resistant hypertension patients, including a large CKD subgroup with limited options and no lab-monitoring burden. The bullish case is further supported by about $52 million in gross proceeds that extend runway beyond near-term catalysts, plus the ongoing 280-patient Phase 2b readout in 1H27, which could validate broader adoption and a substantial commercial opportunity.

Bears say

Retension Pharmaceuticals is a pre-revenue, one-asset clinical-stage company whose value hinges almost entirely on RTN-001, a Phase 2 asset with unproven differentiation in a large study and no guarantee of delivering durable or clinically meaningful blood-pressure reductions. Its investment case is weakened by regulatory and safety uncertainty, potential patent challenges, and the risk that the ongoing Phase 2b trial in resistant hypertension may fail to validate earlier legacy studies or exclude broader uncontrolled hypertension adoption. Commercially, it faces entrenched generic antihypertensives and emerging competitors, while future funding needs could prove dilutive because the company will likely require additional capital beyond the current program.

RTSN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Retension Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

RTSN Analyst Forecast & Price Prediction

Get the latest RTSN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RTSN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Retension Pharmaceuticals Inc (RTSN) Forecast

Analysts have given RTSN a Buy based on their latest research and market trends.

According to 2 analysts, RTSN has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Retension Pharmaceuticals Inc (RTSN)


RTSN Analyst Forecast & Price Prediction

Get the latest RTSN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RTSN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RTSN stock data and trends